Results 11 to 20 of about 246,536 (223)

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Pharmacodynamic Effects of VX-150, a Highly Selective NaV1.8 Inhibitor, in Healthy Male Adults

Pain medicine (Malden, Mass.), 2021
Objective To evaluate the analgesic potential, safety, tolerability, and pharmacokinetics of VX-150, a pro-drug of a highly selective NaV1.8 inhibitor, in healthy subjects.
H. Hijma, P. Siebenga, M. D. de Kam, G. Groeneveld   +3 more
semanticscholar   +1 more source

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors

Journal of Clinical Oncology, 2020
PURPOSE Preclinical studies demonstrated that ATR inhibition can exploit synthetic lethality (eg, in cancer cells with impaired compensatory DNA damage responses through ATM loss) as monotherapy and combined with DNA-damaging drugs such as carboplatin ...
T. Yap, Brent O’Carrigan, M. Penney, J. Lim, Jessica Brown, M. J. De Miguel Luken, N. Tunariu, R. Pérez-López, D. Rodrigues, R. Riisnaes, I. Figueiredo, S. Carreira, B. Hare, K. McDermott, S. Khalique, C. Williamson, R. Natrajan, S. Pettitt, C. Lord, U. Banerji, Jack Pollard, Juanita Lopez, J. D. de Bono   +22 more
semanticscholar   +1 more source

VX-765 reduces neuroinflammation after spinal cord injury in mice

Neural Regeneration Research, 2021
Inflammation is a major cause of neuronal injury after spinal cord injury. We hypothesized that inhibiting caspase-1 activation may reduce neuroinflammation after spinal cord injury, thus producing a protective effect in the injured spinal cord.
J. Chen, Yu‐qing Chen, Yu-Jiao Shi, Shu-qin Ding, Lin Shen, Rui Wang, Qiyi Wang, Cheng Zha, Hai Ding, Jian-Guo Hu, He-zuo Lü   +10 more
semanticscholar   +1 more source

A Randomized Controlled Trial of Local Delivery of a Rho Inhibitor (VX-210) in Patients with Acute Traumatic Cervical Spinal Cord Injury

Journal of Neurotrauma, 2021
Acute traumatic spinal cord injury (SCI) can result in severe, lifelong neurological deficits. After SCI, Rho activation contributes to collapse of axonal growth cones, failure of axonal regeneration, and neuronal loss.
M. Fehlings, Yang Chen, B. Aarabi, F. Ahmad, K. Anderson, T. Dumont, D. Fourney, J. Harrop, Kee D. Kim, B. Kwon, Hari K. Lingam, M. Rizzo, L. Shih, E. Tsai, A. Vaccaro, L. Mckerracher   +15 more
semanticscholar   +1 more source

The geometry of reaction norms yields insights on classical fitness functions for Great Lakes salmon. [PDF]

, 2020
Life history theory examines how characteristics of organisms, such as age and size at maturity, may vary through natural selection as evolutionary responses that optimize fitness.
Breck, James E, Lamberson, PJ, Low, Bobbi S, Rogers, Mark W, Rutherford, Edward S, Simon, Carl P   +5 more
core   +2 more sources

Modeling radiation belt radial diffusion in ULF wave fields: 2. Estimating rates of radial diffusion using combined MHD and particle codes [PDF]

, 2010
[1] Quantifying radial transport of radiation belt electrons in ULF wave fields is essential for understanding the variability of the trapped relativistic electrons.
Elkington, Scot R., Huang, Chia-Lin L., Hudson, Mary K., Spence, Harlan E.   +3 more
core   +2 more sources

VX-659–Tezacaftor–Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles

Canadian Journal of Respiratory Critical Care and Sleep Medicine, 2020
Cystic fibrosis is an autosomal-recessive, multisystem disease that affects ∼80,000 patients worldwide.1,2 It is caused by mutations in the CFTR gene, an epithelial chloride ion channel with varyin...
E. Merman, M. Stanbrook, A. Anand
semanticscholar   +1 more source

Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression. [PDF]

, 2014
Cystic fibrosis (CF) is caused by mutations in the CF transmembrane regulator (CFTR) that result in reduced anion conductance at the apical membrane of secretory epithelia.
Apaja, Pirjo M., Avramescu, Radu G., Bagdany, Miklos, Borot, Florence, Finkbeiner, Walter E., Hegedus, Tamas, Lukacs, Gergely L., Perdomo, Doranda, Phuan, Puay-Wah, Szollosi, Daniel, Veit, Guido, Verkman, Alan S., Wu, Yu-Sheng   +12 more
core   +1 more source

Clinical Activity of an hTERT-Specific Cancer Vaccine (Vx-001) in “Immune Desert” NSCLC

Cancers, 2021
Simple Summary We investigated whether there is any correlation between Vx-001 clinical activity and the tumor immune microenvironment (TIME). Our hypothesis was that Vx-001 should be clinically effective in patients with tumor-infiltrating lymphocyte ...
I. Pateras, A. Kotsakis, M. Avgeris, E. Baliou, Panagiotis Kouroupakis, E. Patsea, V. Georgoulias, Jeanne Menez-Jamet, J. Kinet, K. Kosmatopoulos   +9 more
semanticscholar   +1 more source

VX‐445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

New England Journal of Medicine, 2018
BACKGROUND VX‐445 is a next‐generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector designed to restore Phe508del CFTR protein function in patients with cystic fibrosis when administered with tezacaftor and ivacaftor (VX‐445 ...
D. Keating, G. Marigowda, L. Burr, C. Daines, M. Mall, E. McKone, Bonnie W. Ramsey, S. Rowe, Laura A. Sass, E. Tullis, C. Mckee, S. Moskowitz, S. Robertson, J. Savage, C. Simard, F. van Goor, D. Waltz, F. Xuan, T. Young, J. Taylor-Cousar   +19 more
semanticscholar   +1 more source